featured
Nivolumab Plus Ipilimumab With or Without SBRT for Advanced Merkel Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial
Lancet 2022 Sep 09;400(10357)1008-1019, S Kim, E Wuthrick, D Blakaj, Z Eroglu, C Verschraegen, R Thapa, M Mills, K Dibs, C Liveringhouse, J Russell, JJ Caudell, A Tarhini, J Markowitz, K Kendra, R Wu, DT Chen, A Berglund, L Michael, M Aoki, MH Wang, I Hamaidi, P Cheng, J de la Iglesia, RJ Slebos, CH Chung, TC Knepper, CM Moran-Segura, JV Nguyen, BA Perez, T Rose, L Harrison, JL Messina, VK Sondak, KY Tsai, NI Khushalani, AS BrohlFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.